title: Improving bladder cancer patient care: a pharmacoeconomic perspective.
abstract: Bladder cancer is the most expensive cancer per capita to treat in the US healthcare system. Substantial costs associated with the diagnosis, management and surveillance of bladder cancer account for the bulk of the expense; yet, for that cost, patients may not receive high-quality care. Herein the authors review the sources of expenditure associated with bladder cancer care, review population-level analyses of the quality of bladder cancer care in the USA, and discuss opportunities for quality improvement that may yield greater value for men and women newly diagnosed with bladder cancer.
authors.affiliation: Department of Urology, University of Washington, Seattle, WA, USA. jlgore@u.washington.edu
authors.forename: John L
authors.initials: JL
authors.lastname: Gore
authors.forename: Scott M
authors.initials: SM
authors.lastname: Gilbert
mesh_terms: D003365:Costs and Cost Analysis; D015653:Cystectomy; D005260:Female; D006801:Humans; D008297:Male; D006278:Medicare; D005791:Patient Care / Q000191:economics; D010349:Patient Compliance; D010820:Physicians; D011787:Quality of Health Care / Q000191:economics*; D014481:United States; D001749:Urinary Bladder Neoplasms / Q000191:economics* / Q000401:mortality / Q000473:pathology / Q000628:therapy*